Abstract 1391P
Background
Several successes of clinical trials provide new agents into clinical practice of Advanced Gastric Cancer (AGC) over past ten years. It remains unknown whether these practice-changing results actually change our clinical practice.
Methods
We retrospectively reviewed previously untreated AGC patients who started combination chemotherapy of fluoropyrimidine and platinum between 2007 and 2018. We divided into three groups according to the starting periods. (Group A; 2007-2010, Group B; 2011-2014, Group C; 2015-2018) We compared the clinicopathological features, treatment details and clinical outcomes between three groups.
Results
A total of 1,004 consecutive patients were enrolled and 254 were classified into Group A, 300 were Group B and 450 were Group C respectively. There are more patients with poor performance status, aged, esophagogastric junction adenocarcinoma and primary tumor along with study period. Median overall survival (OS) of three groups were similar (approximately 16 months) and, the statistical differences in OS were not observed in any two groups. However, an improvement in OS between HER2 positive and negative was shown. (HER2 positive vs. negative in Group B; HR 0.80, 95% CI; 0.60-1.06 / Group C; HR 0.68, 95% CI; 0.51-0.90). Conversely, the survival of diffuse-type AGC was almost identical throughout the study period.
Conclusions
Increasing varieties of chemotherapy expanded indication of chemotherapy and change therapeutic strategy. The prolongation of survival could not be observed in the whole population past ten years but, clearly in HER2 positive AGC. Conversely, diffuse-type AGC remain dismal. Further development of biomarker-driven therapy would be warranted in future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Japanese Foundation for Cancer Research.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.